ad: Buying and selling caused it . Just a small joke, LOL. No its not LPC, the $2mm original sale was a good faith move on ZLAS's part, they didn't need the cash and won't need any more until mid 2014.
As to the volume some folks finally are waking up. IMHO
Jim Long and calm
Z160. Granted a patent by the U.S. Patent and Trademark office (USPTO) covering novel formulations of Z160 and extending its patent protection and exclusivity into 2032. United States patent number 8,409,560, entitled “Solid Dispersion Formulations and Methods of Use Thereof,” provides broad coverage for a range of novel Z160 pharmaceutical compositions and methods of using these compositions in the treatment of pain. Z160 is a first-in-class, oral, state dependent, selective N-type calcium channel (Cav 2.2) blocker currently in two Phase 2a clinical trials for the potential treatment of chronic neuropathic pain, including lumbosacral radiculopathy which began in the third quarter of 2012 and postherpetic neuralgia which began in the fourth quarter of 2012. Top line data from both studies are expected to be available late in the second half of 2013.